26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      UNAIDS 90–90–90 targets to end the AIDS epidemic by 2020 are not realistic: comment on “Can the UNAIDS 90–90–90 target be achieved? A systematic analysis of national HIV treatment cascades”

      article-commentary

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Summary box Achieving the United Nations Programme on HIV/AIDS (UNAIDS) 90–90–90 targets will require a viral load-informed care to ensure optimal HIV clinical follow-up and resistance monitoring—this in turn will require significant mobilisation of resources. Maintaining a constant drug supply to satisfy the growing number of potential patients to be put on treatment with current funding trends is almost unattainable. Poor quality and non-uniform data collection tools of the various indicators render evaluation of the evolution of the HIV pandemic extremely difficult. The UNAIDS 90–90–90 agenda is non-inclusive, disease specific and might contribute to weakening health systems which are already challenged by the double burden of communicable and non-communicable diseases. There is indisputable evidence regarding the remarkable success over the past two decades in reducing HIV associated morbidity, mortality, transmission, stigma and improving the quality of life of people living with HIV.1 In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) and partners launched the 90–90–90 targets; the aim was to diagnose 90% of all HIV-positive persons, provide antiretroviral therapy (ART) for 90% of those diagnosed, and achieve viral suppression for 90% of those treated by 2020. This is estimated to result in 73% of people with HIV achieving viral suppression, a crucial step in ending the AIDS epidemic by 2030.2 However, 36.9 million people are living with HIV today and about 2.1 million new infections were recorded in 2015.3 This high rate of new infections continues to fuel the epidemic. Reports from national HIV programmes suggest that the 90–90–90 targets agenda for 2020 risks are unrealistic.4 Early placement of patients on combined ART (cART) and achievement of viral load suppression reduces mortality and HIV transmission and improves quality of life.1 Getting over 90% of people with HIV to know their status can therefore plausibly help achieve the 90–90–90 targets. However, in a recent systematic analysis of national HIV treatment cascades from 69 countries by Levi et al 4 in BMJ Global Health, none of the countries had met the 90–90–90 targets. They found that diagnosis (target one—90% of all HIV-positive people diagnosed) ranged from 87% (the Netherlands) to 11% (Yemen). Treatment coverage (target two—81% of all HIV-positive people on ART) ranged from 71% (Switzerland) to 3% (Afghanistan). Viral suppression (target three—73% of all HIV-positive people virally suppressed) was between 68% (Switzerland) and 7% (China). In 2014/2015, of the 36.9 million of people with HIV globally, only 54% were diagnosed, 41% were on ART and 32% were virally suppressed, demonstrating that we are still very far from achieving the 90–90–90 targets. The lowest achievement rates were in low income and middle income countries (LMICs). Levi et al 4 adequately highlighted the gaps in HIV diagnosis and provision of cART, which may be unattainable under the ambitious UNAIDS 90–90–90 targets given the current trends. However, the targets only make sense if HIV testing is performed under acceptable conditions and appropriate interventions to ensure linkage to care after testing are put in place. Improving the quality of counselling could ameliorate linkage to care, trust and compliance.5 It is no news that social workers and trained psychosocial support staff remain scarce if not inexistent in most healthcare facilities that manage patients with HIV. Without refuting the fact that HIV-associated stigma has reduced significantly worldwide, it still constitutes a hindrance to optimal care, even in developed countries.6–8 Putting adequate and holistic interventions in place requires good data. Levi et al 4 identified lack of good quality data, as well as its non-uniformity, which renders cross-national comparisons difficult. Of the 196 eligible countries, they only found available data on 69 countries for analysis. Paediatric HIV care remains a core hindrance to achieving the 90–90–90 targets. With unacceptably high numbers of HIV-infected children who are not on treatment9 and potential new HIV-infected patients who will be diagnosed and consequently deserve treatment with expanded screening, it is questionable if health systems will be able to meet the demand for and ensure the continuous supply of cART.4 Periodic unavailability of drugs is a key driver of drug resistance. Resistance to first-line therapy is already here, and could get worse if immediate and appropriate action is not taken.10 11 Early detection of treatment failure, adherence counselling and appropriate switching to second-line therapy are key strengths of a viral load monitored model.11 Investing and ensuring the sustainability of a viral load-informed care and monitoring model10 11 must be a priority. This, of course, shall involve mobilisation of resources. Unfortunately, global health challenges go far beyond HIV, and many other leading causes of death and disability also deserve increased attention. Priority setting and health system reforms to manage HIV as a chronic disease must be upheld in government agendas of LMICs. Indeed, non-communicable diseases (NCDs) are set to overtake HIV and other infectious diseases as the top killers in low-income countries (LICs) by 2030. These countries are still ill-prepared to cope with the rising epidemic of cardiovascular diseases (CVDs) and NCDs in general.12 Despite the increasing burden of diabetes mellitus and CVDs in the HIV population, even HIV clinics in these settings are unprepared for the diagnosis and management of NCDs in the context of HIV care.13 Considering the already huge and increasing burden on health systems of diseases other than HIV, inclusive approaches are needed to provide integrated care for both infectious diseases and NCDs to populations at the primary healthcare level. A disease-specific agenda focusing on HIV is therefore self-destructive. Moreover, meeting the future resource needs for ART scale-up under the 90–90–90 scenario (US$18 billion per year globally) will require significant additional resource mobilisation, which may jeopardise funding of other health programmes. Large gaps exist across countries with respect to meeting targets, with highly affected and LIC lagging behind.4 Indeed, before ending the HIV epidemic by 2030, the 90–90–90 strategy would have significantly weakened health systems and impeded the fight against the rising NCDs burden in LICs. Active research and development of community friendly interventions are highly needed.14 This can lead to an increase in screening rates; also, early identification of patients lost to follow-up and addressing of special psychosocial concerns could be achieved.14 Getting good and uniform data constitutes a priority to better monitor, plan and act appropriately within the context of evolving towards meeting these, for the moment elusive targets, especially in LMICs.4 Although Levi et al 4 did not explore linkage to care and retention in their systematic analysis, they highlighted the fact that placement of diagnosed persons on ART shall constitute a key barrier to attaining the 90–90–90 targets in most LMICs. However, political will, appropriate planning and obtaining required funds could be game changers towards reaching these goals.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          HIV infection: epidemiology, pathogenesis, treatment, and prevention.

          HIV prevalence is increasing worldwide because people on antiretroviral therapy are living longer, although new infections decreased from 3.3 million in 2002, to 2.3 million in 2012. Global AIDS-related deaths peaked at 2.3 million in 2005, and decreased to 1.6 million by 2012. An estimated 9.7 million people in low-income and middle-income countries had started antiretroviral therapy by 2012. New insights into the mechanisms of latent infection and the importance of reservoirs of infection might eventually lead to a cure. The role of immune activation in the pathogenesis of non-AIDS clinical events (major causes of morbidity and mortality in people on antiretroviral therapy) is receiving increased recognition. Breakthroughs in the prevention of HIV important to public health include male medical circumcision, antiretrovirals to prevent mother-to-child transmission, antiretroviral therapy in people with HIV to prevent transmission, and antiretrovirals for pre-exposure prophylaxis. Research into other prevention interventions, notably vaccines and vaginal microbicides, is in progress. Copyright © 2014 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            HIV stigma trends in the general population during antiretroviral treatment expansion: analysis of 31 countries in sub-Saharan Africa, 2003-2013.

            HIV-related stigma is associated with increased risk-taking behavior, reduced uptake of HIV testing, and decreased adherence to antiretroviral therapy (ART). Although ART scale-up may reduce HIV-related stigma, the extent to which levels of stigma in the general population have changed during the era of ART scale-up in sub-Saharan Africa is unknown.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Paediatric HIV treatment failure: a silent epidemic

              Paediatric antiretroviral treatment (ART) failure is an under-recognized issue that receives inadequate attention in the field of paediatrics and within HIV treatment programmes. With paediatric ART failure rates ranging from 19.3% to over 32% in resource limited settings, a comprehensive evaluation of the causes of failure along with approaches to address barriers to treatment adherence are urgently needed. In partnership with the local Department of Health, a pilot programme has been established by Medecins Sans Frontieres (MSF) in Khayelitsha, South Africa, to identify and support paediatric HIV patients with high viral loads and potential treatment failure. Through detailed clinical and psychosocial evaluations and adherence support with an innovative counselling model, treatment barriers are identified and addressed. Demographic and clinical characteristics from the cohort show a delayed median start date for ART, prolonged viraemia including a large number of patients who have never achieved viral load (VL) suppression, a low rate of regimen changes despite failure, and a high percentage of pre-adolescent and adolescent patients who have not gone through the disclosure process. Stemming this epidemic of paediatric treatment failure requires programmatic responses to high viral loads in children, starting with improved “case finding” of previously undiagnosed HIV-infected children and adolescents. Viral load testing needs to be prioritized over CD4 count monitoring, and flagging systems to identify high VL results should be developed in clinics. Clinicians must understand that successful treatment begins with good adherence, and that simple adherence support strategies can often dramatically improve adherence. Moreover, appropriate adherence counselling should begin not when the child fails to respond to treatment. Establishing good adherence from the beginning of treatment, and supporting ongoing adherence during the milestones in these children's lives is key to sustaining treatment success in this vulnerable HIV-infected patient population.
                Bookmark

                Author and article information

                Journal
                BMJ Glob Health
                BMJ Glob Health
                bmjgh
                bmjgh
                BMJ Global Health
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                2059-7908
                March 2017
                7 March 2017
                : 2
                : 2
                : e000227
                Affiliations
                [1 ]Athena Institute for Research on Innovation and Communication in Health and Life Sciences, Vrije Universiteit , Amsterdam, The Netherlands
                [2 ]Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I , Yaoundé, Cameroon
                [3 ]Department of Medicine, Groote Schuur Hospital and University of Cape Town , Cape Town, South Africa
                Author notes
                [Correspondence to ] Dr Luchuo Engelbert Bain; lebaiins@ 123456gmail.com
                Article
                bmjgh-2016-000227
                10.1136/bmjgh-2016-000227
                5435269
                28589026
                cc951cdf-e2f1-4a57-8509-77b04fad6be3
                Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

                This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

                History
                : 29 October 2016
                : 3 January 2017
                : 6 January 2017
                Categories
                Commentary
                1506

                Comments

                Comment on this article